Intellia Therapeutics (NASDAQ:NTLA) Given Peer Perform Rating at Wolfe Research

Intellia Therapeutics (NASDAQ:NTLA)‘s stock had its “peer perform” rating reiterated by equities research analysts at Wolfe Research in a research note issued to investors on Wednesday,Benzinga reports.

Several other analysts have also weighed in on NTLA. HC Wainwright decreased their price target on Intellia Therapeutics from $18.00 to $15.00 and set a “buy” rating on the stock in a report on Monday. Jones Trading cut shares of Intellia Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday. Chardan Capital reduced their target price on shares of Intellia Therapeutics from $48.00 to $26.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. William Blair cut shares of Intellia Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Monday, October 27th. Finally, Robert W. Baird set a $9.00 price target on shares of Intellia Therapeutics in a report on Thursday, October 30th. Eleven investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $18.25.

Intellia Therapeutics Trading Up 4.6%

Shares of NASDAQ:NTLA opened at $10.18 on Wednesday. Intellia Therapeutics has a 12 month low of $5.90 and a 12 month high of $28.25. The company has a 50-day moving average price of $17.13 and a 200 day moving average price of $12.56. The company has a market cap of $1.18 billion, a price-to-earnings ratio of -2.38 and a beta of 2.44.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.92) earnings per share for the quarter, topping the consensus estimate of ($1.02) by $0.10. The company had revenue of $13.78 million for the quarter, compared to analysts’ expectations of $14.12 million. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The firm’s revenue for the quarter was up 51.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.34) earnings per share. As a group, equities analysts forecast that Intellia Therapeutics will post -5.07 EPS for the current year.

Insider Buying and Selling

In related news, Director William J. Chase bought 100,000 shares of Intellia Therapeutics stock in a transaction dated Wednesday, August 20th. The shares were acquired at an average cost of $10.03 per share, with a total value of $1,003,000.00. Following the completion of the transaction, the director owned 134,693 shares in the company, valued at $1,350,970.79. The trade was a 288.24% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Michael P. Dube sold 1,871 shares of Intellia Therapeutics stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the sale, the chief accounting officer directly owned 55,266 shares of the company’s stock, valued at $960,523.08. This represents a 3.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 3.10% of the company’s stock.

Institutional Investors Weigh In On Intellia Therapeutics

Hedge funds have recently made changes to their positions in the company. Headlands Technologies LLC bought a new position in shares of Intellia Therapeutics during the 2nd quarter worth $26,000. Blue Bell Private Wealth Management LLC bought a new stake in shares of Intellia Therapeutics in the third quarter valued at about $30,000. Whipplewood Advisors LLC lifted its stake in Intellia Therapeutics by 114,900.0% in the second quarter. Whipplewood Advisors LLC now owns 3,450 shares of the company’s stock worth $32,000 after acquiring an additional 3,447 shares during the period. Northwestern Mutual Wealth Management Co. grew its holdings in Intellia Therapeutics by 56.4% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 4,590 shares of the company’s stock worth $33,000 after acquiring an additional 1,655 shares in the last quarter. Finally, Harbour Investments Inc. increased its position in Intellia Therapeutics by 76.7% during the 1st quarter. Harbour Investments Inc. now owns 5,214 shares of the company’s stock valued at $37,000 after purchasing an additional 2,264 shares during the period. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.